The Indian pharmaceutical market (IPM) has wrapped up FY26 with renewed momentum, signaling a clear turnaround after a period of sluggish demand. The year-end performance highlights a strong recovery in volume growth, driven primarily by chronic therapies such as cardiac and anti-diabetic medicines. This shift not only reflects changing disease patterns in India but also underscores the evolving structure of the pharma industry.
One of the most notable developments in FY26 was the rebound in volume growth. After several quarters of stagnation, PharmaTrac data indicates that volume growth rose to approximately 1.7% in the March 2026 quarter—the highest level seen in over a year. This improvement is significant because it signals real demand recovery, rather than growth being driven solely by price increases, which had been the case in previous quarters.
In terms of overall market performance, the IPM recorded around 10.5% year-on-year growth in value during the March quarter. This steady rise reflects a combination of price stability, improved consumption, and strong demand in key therapy segments. Importantly, the growth trajectory remained consistent throughout the quarter, suggesting a stable and resilient market environment.
A key driver behind this strong performance has been the dominance of chronic therapies. Treatments for long-term conditions such as diabetes, cardiovascular diseases, and central nervous system disorders have seen robust demand. These segments are growing at nearly double the pace of acute therapies, supported by factors like increasing lifestyle diseases, better diagnosis, and improved patient adherence to long-term treatments.
Chronic therapies now account for a larger share of the overall market—over half of total pharma sales—highlighting a structural shift in the industry. Unlike acute treatments such as antibiotics and painkillers, which depend on seasonal or short-term illnesses, chronic medicines ensure sustained demand due to continuous patient usage. This makes them a more stable and profitable segment for pharmaceutical companies.
On the other hand, acute therapies have shown relatively weaker performance. Categories like anti-infectives and pain management drugs struggled to maintain momentum, largely due to lower seasonal illness incidence and changing prescribing patterns. This divergence between chronic and acute segments clearly reflects a transformation in healthcare needs and consumption behavior in India.
Another important aspect of FY26 has been the gradual transition of the market toward a value-driven model. While pricing still contributes to growth, the increasing role of volume expansion indicates healthier market fundamentals. The recovery in unit sales suggests that affordability, accessibility, and healthcare awareness are improving across the country.
Looking ahead, the outlook for the Indian pharmaceutical industry remains positive. Industry estimates suggest sustained growth driven by rising healthcare access, expanding insurance coverage, and increasing prevalence of chronic diseases. Additionally, innovation, specialty drugs, and premium therapies are expected to further boost market value in the coming years.
For pharmaceutical companies, including emerging and established players, this evolving landscape presents significant opportunities. Businesses that focus on chronic segments, invest in product innovation, and strengthen distribution networks are likely to benefit the most. At the same time, maintaining a balance between affordability and quality will remain crucial in a price-sensitive market like India.
In conclusion, FY26 has marked a turning point for the Indian pharma market. The revival in volume growth, coupled with the rising dominance of chronic therapies, indicates a healthier and more sustainable growth pattern. As the industry continues to evolve, it is well-positioned to play a vital role in both domestic healthcare delivery and global pharmaceutical supply.
